Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 1, 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of October 31, 2016:
- Total issued ordinary shares: 5,367,654,061 (25 pence each).
- Shares held in Treasury: 491,505,950.
- Total voting rights: 4,876,148,111.
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document's sole purpose is to establish the denominator for shareholder interest calculations under the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total voting rights count of 4,876,148,111 for compliance reporting thresholds.
- Confirm the number of Treasury shares (491,505,950) when calculating outstanding shares.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for performance metrics.